The First Five-Year Plan (2001-2005)

Renhe Group implemented the First Five-Year Plan from 2001 to 2005. During the "First Five-Year Plan" period, Renhe Group's sales revenue increased from 50 million yuan in 2001 to 1 billion yuan in 2005, with an average annual growth rate of 109.3; its contribution to national tax revenue increased from 1.35 million yuan in 2001 to 6,000 yuan in 2005. million, with an average annual growth rate of 143.6. Remarkable results have been achieved.

The Second Five-Year Plan (2006-2010)

The general outline of Renhe Group’s “Second Five-Year Plan” is: Make full use of the materials obtained from the successful implementation of the first Five-Year Plan conditions and abundant resources, adhere to the strategic policy of two-wheel drive of industrial development and capital operation, adhere to industry as the foundation, marketing as the leader, and scientific research and development as the forerunner, vigorously enhance Renhe's corporate brand and product brand, and achieve scale, branding, and Technology, scientific management, and operational capitalization have built Renhe into a large-scale modern pharmaceutical enterprise group in China's pharmaceutical industry.

Under the strong leadership of the board of directors of Renhe Group with Mr. Yang Wenlong as the core, and through the hard work and hard work of all employees, various goals and tasks of the "Second Five-Year Plan" have been successfully completed. At present, Renhe Group has become a modern pharmaceutical enterprise group with 1 listed company, 8 key industrial production enterprises, 3 commercial sales and logistics enterprises, and more than 5,000 employees.

Compared with the end of the "First Five-Year Plan" period, Renhe Enterprise's sales revenue during the "Second Five-Year Plan" period once again doubled, and its contribution to national tax revenue increased from 60 million yuan in 2005 to 200 million yuan in 2010. And achieved asset appreciation of 3.48 billion yuan.

During the Second Five-Year Plan period, Renhe Pharmaceutical Co., Ltd. was successfully listed on the Shenzhen Stock Exchange of China in March 2007, and successfully completed a private placement in June 2009, achieving excellent results in the capital market. .

During the Second Five-Year Plan period, Renhe Group cooperated with China's outstanding scientific research institutions to establish scientific research and development centers such as the "Modern Traditional Chinese Medicine Preparation Joint Laboratory" and the "Renhe Pharmaceutical Research Institute", and was approved for 5 national high-tech The project has greatly enhanced the company's scientific research and development strength and core competitiveness.

During the Second Five-Year Plan period, through successful brand operation, Renhe Enterprises already has brands such as "Fuyanjie", "Youkadan", "Renhe Kelike", "Shining" and "Qinghuo Capsules". ", "Zhengwei Capsules" and other six well-known products, as well as two well-known Chinese trademarks "Renhe" and "Shining", have become one of the most influential companies in the Chinese pharmaceutical industry.

The Third Five-Year Plan (2011-2015)

In 2010, the Board of Directors of Renhe Group formulated the company's "Three Five-Year Plan" Strategic Outline, which defined Renhe's " The guiding ideology, strategic principles and strategic goals of the "Third Five-Year Plan":

Guiding ideology: Adhering to the corporate purpose of "serving human health", following the corporate philosophy of "people-oriented, harmony is precious", and adhering to the corporate philosophy of "harmony and cooperation" With the theme of winning first, we focus on economic benefits, effectively integrate social resources, make full use of the core advantages formed during the "First Five-Year Plan" and "Second Five-Year Plan", quickly build the core competitiveness of the Third Five-Year Plan, vigorously promote scientific and technological innovation, and vigorously Promote the dual-wheel drive of industry and capital, accelerate corporate development, and maximize corporate benefits, social benefits, and employee interests.

Strategic policy: leading in talent, leading in technology, leading in model and leading in mechanism.

Strategic goal: Through the concerted efforts of all Renhe colleagues, working together, working hard, innovating and developing, and advancing with the times, we will build Renhe into a modern pharmaceutical enterprise group with strong core competitiveness. . By the end of the Third Five-Year Plan, it has achieved annual sales revenue of 10 billion yuan, profits and taxes of 2 billion yuan, and a capital market value of 30 billion yuan, ranking among the top 50 Chinese pharmaceutical companies.